In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
New Frontiers
Read PharmaTimes recent article, featuring ICON expert Tom O'Leary, as he discusses his take on how the Internet of Medical Things (loMT) is evolving the patient role in pharma.
-
Regulatory bottlenecks mean EU clinicians & patients could lose access to medical devices under new rules
A recent press release by Samedan LTD Pharmaceutical Publishers on ICON’s scheduled presentation to be given at The Medtech Conference 2019, ‘MDR/IVDR – What now?’, during which our experts will discuss the findings of the whitepaper ‘Higher Costs & Bottlenecks’, looking at the future implications of the new MDR/IVDR rules on the EU market.
-
Making a Difference
How can we encourage more women to pursue STEM careers? Read how ICON is playing a part in this recent Conversis article.
-
Hasta la vista, maybe? Terminating the Hollywood view of AI in pharma
In drug development, the success of AI depends on gathering the right data and being able to prove its authenticity when an application is subject to regulatory scrutiny. Read this Pharmaceutical Market Europe (PME) article to explore featured commentary from ICON expert Tom O’Leary on the use of AI in the pharmaceutical sector.
-
The evolution of real world studies
Real world evidence is not a new concept, but its influence on drug development decision-makers continues to increase. ICON expert Bill Row discusses how life sciences companies can maximise the use of real world data to support commercial success in this Pharmaceutical Market Europe (PME) article.
-
The modern marketing maze
Pharma is just beginning to scratch the surface of digital as a means of communicating and interacting with patients. Read ICON expert Chuck Stevens' comments on how he and his team are supporting patient/consumer access in this recent PharmaTimes article.
-
MolecularMD Profiled as CDx Developer Making a Mark
From its inception in 2006, the mission of MolecularMD, an ICON plc company, has been to empower therapeutic/diagnostic co-development with strategies that mitigate risk and that nimbly adapt to accelerated approval timelines. Learn more about what makes MolecularMD recognizable as a leader in companion diagnostics development in Clinical OMICs recent article.
-
A Small Biotech Takes On Some Big Clinical Trial Challenges
Explore how a small biotech takes on some big clinical trial challenges in Clinical Leader's recent article.
-
Moving Beyond a Buzzword: How Small- to Mid-sized Biotechs Can Adopt Patient Centricity in Oncology Trials
A BioCentury article authored by ICON experts Lucy Clossick Thomson, Senior Director of Oncology Project Management & Susan Campbell, Director of Patient Recruitment, discussing how even small steps toward patient engagement can improve cancer trial recruitment and reduce costs.
-
America's Best Employers for Women
Read about ICON's recent recognition as a top employer for women in Forbes' 2019 List of America’s Best Employers for Women.
